Surfactant Replacement Therapy in Influenza A H1N1

Skokić, Fahrija; Hudić, Igor; Hotic, Nesad; Belkisa, Colic; Praso, Mirsada; Bacaj, Dubravka

doi:10.1097/inf.0b013e3181cf2eaa

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Врахо вуючи патогенетичний механізм ураження легень при COVID 19, сурфактант замісна терапія може бути корисною в лікуванні цієї когорти пацієнтів. Існує ряд досліджень, що доводять ефективність введення сурфактанту при інших інфекціях [5].…”

Section: клинический случай тяжелой коронавирусной инфекции у ребенка 6 месячного возрастаunclassified

Clinical case of severe coronavirus infection in a 6-month-old child

Похилько¹,

Cherniavska²,

Rossokha³

et al. 2021

MPU

View full text Add to dashboard Cite

Nowadays, the creation of treatment protocols for young children with COVID-19 is especially relevant, as some issues of pathogenesis and genetic determinism of severe lung damage are still unclear. COVID-19-induced respiratory distress syndrome is a predictable severe complication that requires early diagnosis and proper treatment. Given the pathogenetic mechanism of lung damage in COVID-19, surfactant replacement therapy may be useful in the treatment of this cohort of patients. Clinical case. A clinical case of severe coronavirus infection caused by SARS-CoV-2 in a 6-month-old child is presented. The course of the disease was accompanied by severe damage to the lung parenchyma with the development of acute respiratory distress. The examination of the patient confirmed the genetic determinism of severe COVID-19, polymorphic risk alleles of the genes GSTM1, GSTP1, SFTP-B. The child's treatment included not only long-term mechanical ventilation, but also surfactant replacement therapy. The child recovered and was discharged without signs of respiratory failure. Conclusions. This clinical case demonstrates the association of genetic polymorphism with severe virus-induced lung damage. Because severe respiratory failure in COVID-19 is likely to be due to the development of acute respiratory distress syndrome, administration of exogenous surfactant should be considered as a possible treatment option. The research was carried out in accordance with the principles of the Helsinki declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: COVID-19, children, virus-induced respiratory distress syndrome, gene polymorphism, surfactant administration.

show abstract

Section: клинический случай тяжелой коронавирусной инфекции у ребенка 6 месячного возрастаunclassified

Clinical case of severe coronavirus infection in a 6-month-old child

Похилько¹,

Cherniavska²,

Rossokha³

et al. 2021

MPU

View full text Add to dashboard Cite

show abstract

“…Протеїн S відповідає за взаємодію з рецепторами ангіотензинперетворюючого ферменту-2 (ACE-2) в легенях і може використовувати її як спосіб проникнення всередину альвеолярних клітин. Доведено експресію ACE-2 практично у всіх внутрішніх органах людського організму -легенях, тонкому кишечнику, серці, печінці та нирках [15][16][17][18]. Дуже значна частина рецепторів АСЕ-2 знаходиться в альвеолярних клітинах типу II.…”

unclassified

The Outlooks for the Surfactant Replacement Therapy of Covid-19 Induced Respiratory Distress Syndrome in Children

Cherniavska¹,

Pokhylko²,

Rossokha³

et al. 2022

Neonatol. hìr. perinat. med.

View full text Add to dashboard Cite

Nearly 6.5 million people have died worldwide from the COVID-19 pandemic. Improvement of pediatric patients survival depends on the continued provision of basic health services to women and children all over the world. The world scientific community must start more scientific clinical investigations and receive more data in order to know the impact of COVID-19 on children`s health andmortality, and to ensure that children and adolescents do not die from preventable events. Such trends in the spread of morbidity and mortality from COVID-19 require an interdisciplinary approach as soon as possible tofurther contain the spread of the disease and prevent complications in order to improve the quality of life. Insufficiently studied molecular changes in lung morpho-biology due to the action of COVID-19 complicate its clinical treatment. An in-depth genetic mechanisms investigation during pathogenetic disorders caused by virus can help in the development of new treatment methods, in articular, the use of surfactant drugs as a component of basic therapy. Recently, it became known that COVID-19-associated lung damage is characterized by typical pathophysiological changes for RDS. Diffuse alveolar damage occurs due to edema of the interstitium, the formation of hyaline membranes, as well as the proliferation of fibroblasts at the stage of recovery. When COVID-19 affects the lungs, surfactantsynthesis is dysregulated, as viral proteins suppress the expression of regulatory genes. Changes during the reparation process also lead to loss of surfactant function. Surfactant replacement therapy can be an alternative in the treatment of patients with COVID-19-associated lung damage, there are a number of studies that prove the effectiveness of such therapy in other infections. COVID-19 can be especially dangerous for children with chronic lung disease, congenital malformations, previously undiagnosed genetic defects in thesurfactant production system. However, timely use of surfactant replacement therapy can prevent one of the worst complications duringmechanical ventilation - air leakage syndrome.

show abstract

Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy

Islam

Khan

2020

Sci Rep

View full text Add to dashboard Cite

An incomplete understanding of the molecular mechanisms behind impairment of lung pathobiology by COVID-19 complicates its clinical management. In this study, we analyzed the gene expression pattern of cells obtained from biopsies of COVID-19-affected patient and compared to the effects observed in typical SARS-CoV-2 and SARS-CoV-infected cell-lines. We then compared gene expression patterns of COVID-19-affected lung tissues and SARS-CoV-2-infected cell-lines and mapped those to known lung-related molecular networks, including hypoxia induced responses, lung development, respiratory processes, cholesterol biosynthesis and surfactant metabolism; all of which are suspected to be downregulated following SARS-CoV-2 infection based on the observed symptomatic impairments. Network analyses suggest that SARS-CoV-2 infection might lead to acute lung injury in COVID-19 by affecting surfactant proteins and their regulators SPD, SPC, and TTF1 through NSP5 and NSP12; thrombosis regulators PLAT, and EGR1 by ORF8 and NSP12; and mitochondrial NDUFA10, NDUFAF5, and SAMM50 through NSP12. Furthermore, hypoxia response through HIF-1 signaling might also be targeted by SARS-CoV-2 proteins. Drug enrichment analysis of dysregulated genes has allowed us to propose novel therapies, including lung surfactants, respiratory stimulants, sargramostim, and oseltamivir. Our study presents a distinct mechanism of probable virus induced lung damage apart from cytokine storm.

show abstract

Surfactant Replacement Therapy in Influenza A H1N1

Cited by 6 publications

References 3 publications

Clinical case of severe coronavirus infection in a 6-month-old child

Clinical case of severe coronavirus infection in a 6-month-old child

The Outlooks for the Surfactant Replacement Therapy of Covid-19 Induced Respiratory Distress Syndrome in Children

Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy

Contact Info

Product

Resources

About